【gas light blinking on mercedes】AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval
AstraZeneca plc
AZN announced that its lung cancer drug,gas light blinking on mercedes Tagrisso has received full approval from the FDA.
We remind investors that Tagrisso had earlier received accelerated approval in 2015. The approval of the drug will help it to become a standard for the treatment of EGFR T790M mutation-positive, locally-advanced or metastatic non-small cell lung cancer (NSCLC) in adults, whose disease had progressed following first-line EGFR tyrosine kinase inhibitor (TKI) therapy.
Tagrisso, a third generation, irreversible EGFR inhibitor, is now available in more than 45 countries across the globe including the U.S., EU, Japan and China. Tagrisso is now the only approved drug available in the U.S. for NSCLC patients with EGFR T790 mutation.
Shares of AstraZeneca have risen 14% since the beginning of this year, outperforming the Zacks classified Large Cap Pharmaceuticals industry, which increased 6% in the same period.
Full approval of the drug is based on positive data from the phase III study AURA3 trial
Data from the study demonstrated statistically-significant improvement in progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy. The data showed that treatment with Tagrisso reduced risk of disease progression by 70% and improved median progression-free survival (PFS) by 10.1 months compared to of 4.4 months in patients treated with platinum-based doublet chemotherapy.
The trial results were presented at the 17th World Conference on Lung Cancer.
The drug is designed to stop the mutation in virus and prevent it from becoming treatment resistant. Patients are treated with Tagrisso only if they are diagnosed with EGFR T790M mutation in the tumor. Meanwhile, Tagrisso is also being investigated for the treatment of adjuvant and metatstatic first line settings patients, with and without brain metastases. It is also being tested for the treatment of leptomeningeal disease and as combination therapies.
According to the data presented in the press release, lung cancer is a major cause of deaths due to cancer in both men and women. As per the numbers, 15-20% of the patients in the U.S. and Europe with NSCLC are diagnosed with EGFR mutation and approximately two-thirds of these patients develop T790 mutation after initial EGFR TKI therapy.
We are encouraged by the full approval of Tagrisso in the U.S. Uptake of the drug among patients worldwide is increasing steadily. Tagrisso earned revenues of $423 million worldwide in 2016. In the fourth quarter of 2016, the drug recorded sales of $147 million, increasing 10.5% sequentially.
Story continues
We remind investors that Roche Holding AG RHHBY had developed a diagnostic test to identify NSCLC patients with a T790M mutation and are eligible for treatment with Tagrisso. The test was approved by the FDA in Nov 2015.
Zacks Rank & Picks
AstraZeneca carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Vertex Pharmaceuticals Incorporated VRTX and Corvus Pharmaceuticals, Inc. CRVS. Corvus sports a Zacks Rank #1 (Strong Buy) while Vertex carries a Zacks Rank #2 (Buy). You can see
the complete list of today’s Zacks #1 Rank stocks here.
Shares of Vertex have risen 48.4% this year so far while earnings estimates for 2017 have gone up by almost 4% in the past 30 days.
Corvus’ loss estimates narrowed from $3.64 to $3.35 for 2017 over the last 60 days. Shares of the company have risen 45.4% since the beginning of this year.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Astrazeneca PLC (AZN): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Corvus Pharmaceuticals, Inc. (CRVS): Free Stock Analysis Report
To read this article on Zacks.com click here.
View comments
-
Iran watchdog passes law on hardening nuclear stance, halting UN inspectionsRead This Before You Buy Advanced Share Registry Limited (ASX:ASW) Because Of Its P/E RatioShould You Investigate AVX Corporation (NYSE:AVX) At US$15.07?Ten Key Components to Sustaining a Small Law FirmCulp: Q2 Earnings InsightsWGA Votes Overwhelmingly for New Code of Conduct, Agents Have a Week to Negotiate Before They’re FiredBig banks look to cut back, alter credit card rewards programs -WSJCosmose Continues to Revolutionize Global Advertising With Launch of Its OMNIcookie Technology in U.S.Look at American Airlines Stock Through a Wider LensShameless, House of Lies and Californication: Showtime Sets Return Dates, Shares Teasers
下一篇:LOPE SHAREHOLDER ALERT: Lawsuit Filed For Grand Canyon Investors
- ·AGI or RGLD: Which Is the Better Value Stock Right Now?
- ·Fed policy turn not good news for Trump as risks mount
- ·US STOCKS-Bank, energy stocks lift Wall Street higher in choppy session
- ·USD/JPY Keeps Rising Despite Chunky Japanese Profits
- ·U.S. Stocks Set To Open Higher On Final Day Ahead Of U.S. Presidential Election
- ·MGM, AEG to break ground on Las Vegas Strip arena
- ·Euro zone factories ended 2018 on a low note - PMI
- ·S&P 500 posts best January since '87, Dow best since '89
- ·Equitrans Midstream Corporation (ETRN) Stock Moves -1.99%: What You Should Know
- ·Exclusive - Indonesia hopes for additional $10 bilion inflows after S&P upgrade, president says
- ·Trump Watch: Behind the Scenes on Trump's Latest 9th Circuit Picks | A Look at the Busy Week Ahead
- ·Government Shutdown Means You May Not See Any New Beers or Wines for a While
- ·Bank of Baroda rolls back charges after public outcry
- ·GBP/USD Forecast: Triple Troubles Pound the Pound
- ·5 Physician Memoirs Every Premed Should Read
- ·Can We See Significant Institutional Ownership On The Ceconomy AG (FRA:CEC) Share Register?
- ·Russia asks for ships disinfection from Iran, Italy and South Korea in Novorossiisk - document
- ·Frank Lloyd Wright-designed Phoenix home for sale for $12.9M
- ·Do Insiders Own Lots Of Shares In Mariner Corporation Limited (ASX:MCX)?
- ·What To Know Before Buying Cabot Microelectronics Corporation (NASDAQ:CCMP) For Its Dividend
- ·Equitrans Midstream Corporation (ETRN) Stock Moves -1.99%: What You Should Know
- ·Netflix poaches CFO from Activision Blizzard - source
- ·US STOCKS-Bank, energy stocks lift Wall Street higher in choppy session
- ·Resolutions for 2019 the tech industry should really, really consider
- ·TREASURIES-U.S. 10-year yield stays below 1% as coronavirus fears persist
- ·With new subway line open, NY transit agency chief to retire
- ·EUR/USD Bullish Break Kick Starts Reversal to 1.13?
- ·BRIEF-Seazen Holdings Says Jan Contract Sales Up 6.55 Percent Y/Y
- ·San Bernardino shooting lawsuits vs Facebook, Google, Twitter dismissed
- ·Do Directors Own Vonex Limited (ASX:VN8) Shares?
- ·HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages VMware (VMW) Investors Who Have Suffered Significant Losses to Contact its Attorneys: Securities Fraud Class Action Deadlines Established
- ·7 of Hillary Clinton’s Biggest Flip-Flops
- ·Over 900 Retailers Now Accepting Bitcoin Cash
- ·Here's How 6 Credit Card Applications in 1 Day Affected My Credit Score
- ·Crude Oil Price Update – Close Over $35.79 Forms Potentially Bullish Closing Price Reversal Bottom
- ·The Dan Marino Foundation and Panera Bread to Commemorate National Autism Awareness Month With the 6th Annual Touchdown For Autism!